ABSTRACT
Obesity is currently emerging as a global epidemic, affecting 10% of adult population worldwide. The primary objective of the current systematic review is to describe the trend of overall prevalence of obesity in Iranian women and men through a meta-analysis. We searched the medical literature published from 1990 to 2007 in Medline [PubMed], EMBASE database, and the Iranian digital library. All published reports of research projects, papers in relevant congresses, unpublished crude data analysis, proceedings, books and dissertations were reviewed. Data from eligible papers that fulfilled the qualification criteria entered meta-analysis [Random Model]. Data from 209,166 individuals were analyzed. The overall prevalence of obesity in adults was 18.5% [95%CI: 15.1-21.8], respectively. The prevalence of obesity in men and women was 12.9% [95%CI: 10.9-14.9] and 26.2% [95%CI: 21.3-30.5], respectively. The trend of obesity was similar in both genders; women had almost a constantly higher risk of obesity than men during the recent two decades. Data from 209,166 individuals were analyzed. The overall prevalence of obesity in adults was 18.5% [95%CI: 15.1-21.8], respectively. The prevalence of obesity in men and women was 12.9% [95%CI: 10.9-14.9] and 26.2% [95%CI: 21.3-30.5], respectively. The trend of obesity was similar in both genders; women had almost a constantly higher risk of obesity than men during the recent two decades
ABSTRACT
Introduction: the addition of ribavirin [RIBA] to the standard treatment with interferon [IFN] alpha led to an improvement in sustained virologic response [SVR] from less than 20% with IFN monotherapy to 40-45% in combination therapy. The aim of this study is to assess the therapeutic efficacy and safety of IFN alpha [PDferon B®] in combination with RIBA on Iranian patients with chronic hepatitis C [CHC]
Methods: 48 naive patients aged 18 years or more with CHC were enrolled and treated with 3 mega units [MU] IFN alpha-2b three times a week plus 800-1000 mg RIBA per day for 48 weeks. Follow-up after therapy was 6 months. The efficacy was evident at the end of treatment and at the end of follow-up in terms of sustained normalization of alanine aminotransferase and sustained serum HCV-RNA loss
Results: the rate of sustained biochemical and virologic response were 68.3% and 78%, respectively. Virologic response was 80.9% and 86.4% at weeks 12 and 48 as well. Any patient didn't have serious complication
Conclusion: although we had no control group who used standard IFN, our preliminary finding showed acceptable and promising response rate of PDferon. On the other hand, it seems that adverse events with PDferon are as like as other standard IFNs
ABSTRACT
A 36-years old man was treated with Peg-interferon [PEGASYS] and ribavirin to control of Hepatitis C experienced a suicide attempt and was admitted to hospital. Another case, treated by PDferon B® attempted to suicide by consumption more than 100 tablet of Fluxetin. Fortunately their family rescued them. Both of them had a history of depression and interferon-alpha deepened it. These are the first reports of suicide attempt after treatment with PEGASYS and PDferon B® from Iran
ABSTRACT
Background and aims: pegylation of Interferon prolongs the medication half-life, which has resulted in introducing Pegylated Interferon [PEG-IFN] as the new modality for treatment of chronic hepatitis C. This clinical trial was conducted to assess the efficacy and safety of Peg-INF in combination with ribavirin in a number of Iranian patients with chronic hepatitis C or cirrhosis
Methods: fifty-two patients with HCV RNA in serum, persistently elevated aminotransferase levels, and chronic hepatitis [n=45] or cirrhosis [n=7] on liver biopsy were enrolled to this study. The patients received PEG-IFN [40 kD] 180 micg per week plus ribavirin 10- 15 mg/kg per day. Treatment lasted 48 weeks and was followed by a 24-week follow up period to assess sustained virologic response [SVR]. The patients consisted of 46 males and 6 females with a mean age of 38.5 +/- 10.9 years
Results: in an intention-to-treat analysis HCV RNA was undetectable in 43 patients [83.7%] at week 48 and SVR was achieved in 28 patients [53.8%]. SVR was achieved in 62.9% of naïve patients, 35.3% of the patients who had a past failed treatment with IFN-based therapy, 60.0% of patients with chronic hepatitis and 14.3% of cirrhotic patients. In two patients [3.8%] adverse event led to treatment discontinuation and in eight patients [15.3%] dose modification of medication was required
Conclusion: this study showed that combination therapy with PEG-IFN plus ribavirin was associated with a promising SVR rate and acceptable tolerability in Iranian patients. This regimen may be effective for patients who failed prior IFN-based treatment